AD-Detect — A Blood Test for Alzheimer's Disease
AD-Detect — A Blood Test for Alzheimer's Disease
October 30, 2023 (Issue: 1688)
AD-Detect (Quest), a blood test to evaluate
Alzheimer's disease risk, is being marketed directly
to consumers. It has not been cleared or approved
by the FDA (laboratory-developed tests like this
one currently do not need FDA authorization to...more
- O Hansson et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement 2022; 18:2669. doi:10.1002/alz.12756
- MV Pais et al. Plasma biomarkers of Alzheimer’s disease: a review of available assays, recent developments, and implications for clinical practice. J Alzheimers Dis Rep 2023; 7:355. doi:10.3233/adr-230029
- AL Brand et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther 2022; 14:195. doi:10.1186/s13195-022-01117-1
- S Janelidze et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol 2021; 78:1375. doi:10.1001/jamaneurol.2021.3180
- SE Schindler et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 93:e1647. doi:10.1212/wnl.0000000000008081
- Y Li et al. Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology 2022; 98:e688. doi:10.1212/wnl.0000000000013211
- KV Giudici et al. Assessment of plasma amyloid-β42/40 and cognitive decline among community-dwelling older adults. JAMA Netw Open 2020; 3:e2028634. doi:10.1001/jamanetworkopen.2020.28634
- DM Weber et al. A new LC-MS/MS assay for the quantification of Aβ40 and Aβ42 in plasma: validation and clinical performance. Alzheimers Dement 2022; 18(S6):e064182. doi:10.1002/alz.064182
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: AD-Detect — A Blood Test for Alzheimer's Disease
Article code: 1688b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
